Display search results for ** instead (38 products)

Showing 21-30 of 38

This issue of Vital Signs, released on September 30, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology and Connected Health.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on October 31, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, In Vitro Diagnostics, and Advanced Medical Technology.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on November 22, 2013, provides overview of global IVD market dynamics, discuss growth strategy, and explore early opportunities in the African IVD market. Additionally, a company spotlight is provided for Global BioDiagnostics based in Temple, Texas. The company is focused on developing affordable diagnostic tes...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on January 17, 2014, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for our core markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology, and Connected Health.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on September 30, 2013, provides a market overview and drug pipeline analysis of Type 2 diabetes therapeutics. Additionally, a company spotlight is provided for Trovagene in San Diego, CA. The company has a proprietary transrenal nucleic acid platform with the potential to deliver superior molecular diagnostics i...

USD 450.00

USD 337.50 save 25 %

Given the importance of the changes from PPACA and the creation of the health insurance marketplaces, we are providing our online Frost.com blog on HIX in collected form for the month of September for ease of use by our subscription clients. This discussion is brought to you by our Connected Health research program. Please also follow our blog, par...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm and what these deals mean for the industry. Additionally, Illuminas first stab at personalized medicine through a partnership with Amgen is explored.

USD 450.00

USD 337.50 save 25 %

Given the importance of the changes from PPACA and the creation of the health insurance marketplaces, we are providing our online Frost.com blog on HIX in collected form for the month of August for ease of use by our subscription clients. This discussion is brought to you by our Connected Health research program. Please also follow our blog, part o...

USD 450.00

USD 337.50 save 25 %

Given the importance of the changes from PPACA and the creation of the health insurance marketplaces, we are providing our online Frost.com blog on HIX in collected form for the month of September for ease of use by our subscription clients. This discussion is brought to you by our Connected Health research program. Please also follow our blog, par...

USD 450.00

USD 337.50 save 25 %

The wearables market is currently a center of hype and interest across the varied landscape of consumers, vendors, providers, payers, and other stakeholders interested in the broader digital health market. Companies are trying to better understand consumer habits, exploring device monetization outside of the early adopting fitness crowd, increasing...

USD 450.00

USD 337.50 save 25 %

Showing 21-30 of 38